Based in India’s commercial capital Mumbai, The Chemical, Industrial & Pharmaceutical Laboratories, currently Cipla was founded by Khwaja Abdul Hamied in the year 1935.

K A Hameid gave the company all his patent and proprietary formulas for several drugs and medicines, without charging any royalty. On August 17, 1935, Cipla was registered as a public limited company with an authorized capital of ` 6 lakhs. Cipla started marketing its product on September 22, 1937.

Today, Cipla is a leading player in anti-infective and anti-asthmatic formulations. The company also specializes in the manufacturing of steroids and hormones.

Cipla received clearance from the Drugs Controller General of India to manufacture and market the country's first nonnucleoside reverse transcriptase inhibitor (NNRTI), evirapine, for the treatment of AIDS.

Prepared by: Hiralal Arsiddha 17th January 2011.

Profile of the Company

Cipla Ltd is India’s No:1 Pharma Company

Date of Incorporation – 17th August 1935.

Corporate Office – Mumbai

Plant Locations Baddi – Manufacturing Formulation Goa – Manufacturing Formulation Indore – Manufacturing Formulation Sikkim – Manufacturing Formulation Bangalore – Manufacturing Bulk Drugs & Formulation (R & D Bulk Drug) Kurkumbh - Manufacturing Bulk Drugs & Formulation (R & D Bulk Drug) Patalganga – Manufacturing Bulk Drugs & Formulation (R & D Bulk Drug) Vikroli – R & D Bulk Drugs & Formulation

Key Competitors Sun Pharma Dr Reddys Labs Glaxo Smith Kline Lupin Ltd

2Prepared by: Hiralal Arsiddha7th January 2011.

3Prepared by: Hiralal Arsiddha

Global Presence of Cipla

7th January 2011.

Key Products

4Prepared by: Hiralal Arsiddha

Azipro Febucip Flo Soft Immudrops Lacsyp

levolin autohaler Panstal Pirfenex Sornip Cream Zolmist

7th January 2011.

Revenue Break-up

5Prepared by: Hiralal Arsiddha7th January 2011.

Some Key Financial Details

Sr. No. Particulars Value in % Terms

1 Current Market Price ` 372.50

2 Total Market Capitalization ` 29691.24(in crore)

3 Shareholders Capital ` 5905.12(in crore)

4 Total Long Term Debts ` 5.07(in crore)

5 Net Debts ` -55.77(in crore)

6 Enterprise Value ` 29635.47(in crore)

7 Earning Per Share ` 13.69

8 PE Ratio 27.43

9 Return on average equity 18.31%

6Prepared by: Hiralal Arsiddha7th January 2011.

Share Holding Pattern

7Prepared by: Hiralal Arsiddha7th January 2011.

Management

8Prepared by: Hiralal Arsiddha

Name Designation Qualification

Dr. K.A. Hamied Founder BSc., M.A., Ph.D.

Dr. Y.K. Hamied Chairman & Managing Director Ph.D. (in Chemistry)

Mr. M.K. Hamied Joint Managing Director B.Com

Dr. Amar Lulla Joint Managing Director M.B.B.S.

Mr. S. Radhakrishnan Whole-time Director Chartered Accountant

Mr. V.C. Kotwal Non-Executive Directors LL.B.

Dr. H.R. Manchanda Non-Executive Directors M.B.B.S., Consultant surgeon at Breach Candy

Mr. M.R. Raghavan Non-Executive Directors BSc. Chartered Accountant

Mr. Ramesh Shroff Non-Executive Directors LL.B

Mr. Pankaj Patel Non-Executive Directors Science & Law Graduate

7th January 2011.

Recent News/Events

Amar Lulla ceases to be JMD from Dec.13th 2010.

Cipla on Dec. 30th 2010. said it has received fresh notices from National Pharmaceutical Pricing Authority (NPPA) for ` 73.16 crore for overpricing of two drugs.

In keeping with its commitment to reduce mother-to-child transmission of HIV/AIDS, Cipla, one of the world's leading generic pharmaceutical companies has developed the first-of-its kind ‘Mother-Baby Pack' in collaboration with UNICEF and other partners . (Nov. 30th 2010.)

Piramal Healthcare Limited and Cipla Limited signs agreement for purchase of all intellectual property rights in India related to "i-pill" for an aggregate consideration of ` 95 crore. (Mar. 23rd 2010.)

The board of Cipla in its meeting on 11 November 2010 has appointed S. Radhakrishnan as additional director and whole-time director of the company for a period of 5 years.

9Prepared by: Hiralal Arsiddha7th January 2011.

10Prepared by: Hiralal Arsiddha7th January 2011.